Monday, 24 November 2008

Buy Natco Pharma: LKP Shares

LKP Shares has recommended a buy rating on Natco Pharma in its research report. "Although the generic launch of Copaxone used in treatment of multiple sclerosis is more than two years away during which Natco could face litigation from Teva as it is a USD 1.5 billion drug, we believe that the signing of the exclusive supply and distribution agreement with Mylan for the generic version of the drug is a huge long-term positive for Natco. Natco trading at half its book value has robust EBIDTA margins of 22% and we are positive on the longterm prospects at 3xFY'09E earnings. We rate the stock as a BUY," says LKP Shares' research report.

Disclaimer: The views and investment tips expressed by investment experts on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Source: Moneycontrol

No comments:

Post a Comment

DISCLAIMER: The author is not a registered stockbroker nor a registered advisor and does not give investment advice. His comments are an expression of opinion only and should not be construed in any manner whatsoever as recommendations to buy or sell a stock, option, future, bond, commodity, index or any other financial instrument at any time. While he believes his statements to be true, they always depend on the reliability of his own credible sources. The author recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction, before making any investment decisions, and that you confirm the facts on your own before making important investment commitments.